Edgar Lerma, MD, provides insights into the pathophysiology of IgA nephropathy (IgAN) and the therapeutic promise of ...

PRINCETON, NJ, USA & TOKYO, Japan I March 31, 2025 I Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd.

Miller, M.D., co-founder, president and chief executive ... to placebo utilizing the rigorous endpoint of EASI 75 and IGA 0 or 1. Our Phase 3 registration clinical trial in peripheral T cell lymphoma ...

On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for accelerated approval planned ...

Vertex Pharmaceuticals Incorporated today announced several updates on the Company's type 1 diabetes (T1D) portfolio. VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of the ...

Today’s data show that more work needs to be done to advance the ‘cells plus device’ program, and we are committed to doing so,” said Carmen Bozic, M.D., Executive Vice President ...

By Rayk Riechmann As one of the brightest emerging biotechnology companies, Climb Bio Inc. (NASDAQ: CLYM) aims to improve the efficacy of autoimmune disease treatment. With its recently acquired lead ...

They trim our hair, polish our nails and ease our tired muscles - but beauticians, manicurists, hairdressers and barbers can ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its executive team will present and host 1x1 meetings at the Stifel 2025 Virtual ...

The biotech industry may be cooling off, but there’s still plenty to be excited about when it comes to the underlying ...

Gene-editing therapy Casgevy has been approved for over a year in treating sickle cell disease and transfusion ... as its commercial launch ramps up. I'm especially optimistic about the prospects ...